MARKET

GLMD

GLMD

Galmed Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.320
+0.100
+3.11%
Closed 16:00 10/19 EDT
OPEN
3.280
PREV CLOSE
3.220
HIGH
3.370
LOW
3.280
VOLUME
25.64K
TURNOVER
--
52 WEEK HIGH
7.38
52 WEEK LOW
3.020
MARKET CAP
70.10M
P/E (TTM)
-2.8774
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Galmed and Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announces today that they have entered into a research agreement aiming at combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment
PR Newswire · 09/10 12:49
Gannex And Galmed Announce Research Collaboration For Aramchol And ASC41
SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- GannexPharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announces
Benzinga · 09/09 10:33
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 17:23
Galmed EPS beats by $0.06
Galmed (NASDAQ:GLMD): Q2 GAAP EPS of -$0.26 beats by $0.06. As of June 30, 2020, cash and equivalents of $5.55M vs. $15.93M as of December 31, 2019. Press
seekingalpha · 08/06 16:03
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or
PR Newswire · 08/06 11:00
Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases provides today updated information on the Company's pipeline program.
PR Newswire · 08/06 10:50
Galmed Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on Thursday August 6
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a Phase 3 clinical trial for the treatment of nonalc
PR Newswire · 07/30 12:30
64 Biggest Movers From Yesterday
Gainers InnerWorkings, Inc. (NASDAQ: INWK) shares jumped 115.9% to close at $2.85 on Thursday after HH Global announced plans to acquire the company for $3 per share.
Benzinga · 07/17 09:08
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLMD. Analyze the recent business situations of Galmed Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GLMD stock price target is 19.60 with a high estimate of 29.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 44
Institutional Holdings: 8.68M
% Owned: 41.11%
Shares Outstanding: 21.11M
TypeInstitutionsShares
Increased
8
1.28M
New
9
-857.02K
Decreased
4
74.37K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
President/Chief Executive Officer/Director
Allen Baharaff
Chief Financial Officer
Yohai Stenzler
Chief Operating Officer
Guy Nehemya
Chief Scientific Officer
Liat Hayardeny
Other
Tali Gorfine
Lead Director/Independent Director
David Sidransky
Director
Marshall Heinberg
Director
Ran Oren
Independent Director
Carol Brosgart
Independent Director
William Marth
Independent Director
Shmuel Nir
Independent Director
Tal Yaron-Eldar
Independent Director
Tali Yaron-Eldar
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GLMD
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Galmed Pharmaceuticals Ltd stock information, including NASDAQ:GLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLMD stock methods without spending real money on the virtual paper trading platform.